Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-06-25

Clinical Trial Update: Bevacizumab in Treating Patients With Angiosarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab for angiosarcoma has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bevacizumab (bevacizumab)

Snippet

Sponsor: Northwestern University | Conditions: Sarcoma | Phase 2 | Status: COMPLETED | Results posted: 2018-06-25